Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study.
Bodensohn R, Kolorz A, Reis J, Werner S, Forbrig R, Garny S, Taugner J, de Colle C, Belka C, Manapov F, von Baumgarten L, Niyazi M. Bodensohn R, et al. Transl Lung Cancer Res. 2024 Jul 30;13(7):1635-1648. doi: 10.21037/tlcr-24-132. Epub 2024 Jul 25. Transl Lung Cancer Res. 2024. PMID: 39118877 Free PMC article.
FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls.
Holzgreve A, Nitschmann A, Maier SH, Büttner M, Schönecker S, Marschner SN, Fleischmann DF, Corradini S, Belka C, la Fougère C, Bodensohn R, Albert NL, Niyazi M. Holzgreve A, et al. Among authors: bodensohn r. Radiother Oncol. 2024 Sep;198:110386. doi: 10.1016/j.radonc.2024.110386. Epub 2024 Jun 14. Radiother Oncol. 2024. PMID: 38880414 Free article. Review.
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06).
Maier SH, Schönecker S, Anagnostatou V, Garny S, Nitschmann A, Fleischmann DF, Büttner M, Kaul D, Imhoff D, Fokas E, Seidel C, Hau P, Kölbl O, Popp I, Grosu AL, Haussmann J, Budach W, Celik E, Kahl KH, Hoffmann E, Tabatabai G, Paulsen F, Holzgreve A, Albert NL, Mansmann U, Corradini S, Belka C, Niyazi M, Bodensohn R. Maier SH, et al. Among authors: bodensohn r. Clin Transl Radiat Oncol. 2024 May 4;47:100790. doi: 10.1016/j.ctro.2024.100790. eCollection 2024 Jul. Clin Transl Radiat Oncol. 2024. PMID: 38765202 Free PMC article.
Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).
Bodensohn R, Fleischmann DF, Maier SH, Anagnostatou V, Garny S, Nitschmann A, Büttner M, Mücke J, Schönecker S, Unger K, Hoffmann E, Paulsen F, Thorwarth D, Holzgreve A, Albert NL, Corradini S, Tabatabai G, Belka C, Niyazi M. Bodensohn R, et al. Clin Transl Radiat Oncol. 2023 Dec 3;45:100706. doi: 10.1016/j.ctro.2023.100706. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2023. PMID: 38116137 Free PMC article.
Response to the letters to the editor of S. Benkhaled et al. and C.H. Rim regarding the article "Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4-10 brain metastases: A nonrandomized controlled trial" by Bodensohn et al.
Bodensohn R, Niyazi M. Bodensohn R, et al. Radiother Oncol. 2023 Dec;189:109888. doi: 10.1016/j.radonc.2023.109888. Epub 2023 Sep 9. Radiother Oncol. 2023. PMID: 37690665 Clinical Trial. No abstract available.
29 results